Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.

No Thumbnail Available
Authors
Petrie, J R [et al]
REMOVAL Study Group inc. collaboration from:
Shore, Angela
Miller, C.
Warren, Roderick
Journal
Lancet: Diabetes & Endocrinology
Type
Journal Article
Publisher
Elsevier
Rights
Archived with thanks to The lancet. Diabetes & endocrinology
Metformin might reduce insulin requirement and improve glycaemia in patients with type 1 diabetes, but whether it has cardiovascular benefits is unknown. We aimed to investigate whether metformin treatment (added to titrated insulin therapy) reduced atherosclerosis, as measured by progression of common carotid artery intima-media thickness (cIMT), in adults with type 1 diabetes at increased risk for cardiovascular disease.
Citation
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. 2017 Lancet Diabetes Endocrinol
Note